{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:13:33Z","timestamp":1769516013967,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019650","name":"Vir Biotechnology Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jhepr.2025.101400","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T01:31:06Z","timestamp":1742693466000},"page":"101400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4231-3422","authenticated-orcid":false,"given":"Jiayi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7034-8853","authenticated-orcid":false,"given":"Ashley N.","family":"Terrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Corti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6103-8078","authenticated-orcid":false,"given":"Florian A.","family":"Lempp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9605-9458","authenticated-orcid":false,"given":"Andreas S.","family":"Puschnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101400_bib1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra2212151","article-title":"Hepatitis D virus infection","volume":"389","author":"Asselah","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101400_bib2","article-title":"Hepatitis D virus infection: pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022","volume":"5","author":"Lampertico","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101400_bib3","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2025.101400_bib4","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.29574","article-title":"Genetic diversity and worldwide distribution of the deltavirus genus: a study of 2,152 clinical strains","volume":"66","author":"Gal","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101400_bib5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101400_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101400_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.15410","article-title":"Interferon-based treatment of chronic hepatitis D","volume":"43","author":"Sandmann","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101400_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jhep.2023.05.023","article-title":"Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials","volume":"79","author":"Gane","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101400_bib9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2023.07.003","article-title":"Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice","volume":"79","author":"Lempp","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101400_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.06.022","article-title":"Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies","volume":"145","author":"Smee","year":"2017","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2025.101400_bib11","series-title":"Characterization of BJT-778, an anti-HBsAg neutralizing monoclonal antibody for treatment of hepatitis B virus and hepatitis D virus infections, EASL Congress 2024, Poster WED-366, Milan, Italy","author":"Ramos","year":"2024"},{"key":"10.1016\/j.jhepr.2025.101400_bib12","series-title":"Hepatitis B antibodies. Patent WO 2019\/229699 A1","author":"Ewert","year":"2019"},{"key":"10.1016\/j.jhepr.2025.101400_bib13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"L\u00fctgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101400_bib14","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1021\/acsinfecdis.8b00192","article-title":"Hepatitis B virus therapeutic agent ARB-1740 has inhibitory effect on hepatitis delta virus in a new dually-infected humanized mouse model","volume":"5","author":"Ye","year":"2019","journal-title":"Acs Infect Dis"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:56:56Z","timestamp":1749196616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2589555925000771"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101400","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101400"}}